Serotonin 5-HT1D receptor neurons represent a specialized population of neurons expressing the 5-HT1D subtype of serotonin receptors. These neurons play critical roles in modulating neurotransmission throughout the central nervous system and have emerged as important therapeutic targets in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. [1]
The 5-HT1D receptor is one of the oldest identified serotonin receptor subtypes and is highly conserved across mammalian species. It functions primarily as an autoreceptor on serotonergic nerve terminals, where it regulates serotonin release through negative feedback mechanisms. Additionally, 5-HT1D receptors are expressed on non-serotonergic neurons where they function as heteroreceptors modulating the release of other neurotransmitters including glutamate, GABA, and dopamine. [2]
The 5-HT1D receptor is a G protein-coupled receptor (GPCR) that signals through Gi/o protein-mediated inhibition of adenylate cyclase, resulting in reduced intracellular cAMP levels. This signaling cascade leads to hyperpolarization of neuronal membranes through activation of inwardly rectifying potassium channels, thereby reducing neuronal excitability and neurotransmitter release. [3]
5-HT1D receptor neurons are widely distributed throughout the brain and peripheral nervous system. In the human brain, high expression levels are found in the basal ganglia, hippocampus, cortex, brainstem, and spinal cord. The receptor is also expressed in the trigeminal ganglion, where it plays a key role in migraine pathophysiology. [1:1]
| Property | Value |
|---|---|
| Receptor Type | 5-HT1D (HTR1D) |
| Gene | HTR1D |
| Chromosome | 1p36.12 |
| Family | 5-HT1 (Gi/o-coupled) |
| Signaling Mechanism | Gi protein-coupled, inhibits adenylate cyclase |
| Primary Location | Basal ganglia, hippocampus, cortex, brainstem, trigeminal ganglion |
| Ligand Affinity | High for serotonin, moderate for sumatriptan |
The 5-HT1D receptor activates multiple intracellular signaling cascades:
These signaling mechanisms enable 5-HT1D receptors to exert both rapid synaptic effects and longer-term modulatory actions on neuronal function. [4]
In Alzheimer's disease, 5-HT1D receptor expression is significantly altered in regions vulnerable to neurodegeneration. Post-mortem studies have demonstrated:
The loss of 5-HT1D receptors may contribute to the serotonergic dysfunction observed in AD, including disturbances in mood, sleep, and circadian rhythm regulation. [5]
Interestingly, 5-HT1D receptors appear to interact with amyloid-beta pathology. In vitro studies show that 5-HT1D activation can reduce amyloid-beta-induced neurotoxicity through MAPK-dependent mechanisms, suggesting a potential neuroprotective role. [6]
5-HT1D receptor dysfunction is increasingly recognized in Parkinson's disease:
These changes may relate to:
The 5-HT1D receptor has attracted interest as a potential target for treating non-motor symptoms in PD, including depression and sleep disorders.
Lewy Body Dementia: 5-HT1D receptors are affected in both dementia with Lewy bodies and Parkinson's disease dementia. The receptor changes correlate with alpha-synuclein burden in cortical and subcortical regions. [8]
Huntington's Disease: Studies have identified reduced 5-HT1D binding in the striatum and cortex, contributing to the serotonergic dysfunction characteristic of HD. [9]
Multiple System Atrophy: Altered 5-HT1D expression patterns reflect the neurodegenerative processes affecting multiple neurotransmitter systems in this disorder.
As an autoreceptor on serotonergic neurons, 5-HT1D plays a critical role in regulating serotonin neurotransmission:
This autoreceptor function provides a crucial negative feedback mechanism that maintains serotonin homeostasis in the brain.
5-HT1D receptors also function as heteroreceptors on non-serotonergic neurons:
This broad heteroreceptor function positions 5-HT1D receptors as master regulators of neurotransmission across multiple transmitter systems.
5-HT1D receptors in the trigeminal ganglion and spinal cord play important roles in pain processing:
The receptor's location on trigeminal nerve endings allows direct inhibition of pain signaling, explaining the efficacy of triptans in migraine treatment. [@degrroot2019]
The 5-HT1D receptor represents a promising therapeutic target for:
Recent research has identified several promising therapeutic strategies:
5-HT1D receptors interact with brain iron metabolism, which is relevant to both AD and PD pathogenesis. The receptor may modulate iron transport and storage in neurons, and altered iron homeostasis is a feature of many neurodegenerative conditions. [11]
The 5-HT1D receptor was originally identified in the late 1980s as a novel serotonin receptor subtype distinct from the previously characterized 5-HT1 and 5-HT2 families. Early studies focused on its role in migraine pathophysiology, leading to the development of the triptan class of antimigraine drugs.
Subsequent research has revealed broader roles for 5-HT1D receptors in:
The potential of 5-HT1D receptors as therapeutic targets in neurodegenerative diseases has gained attention in recent years, with ongoing research exploring both agonist and antagonist approaches depending on the disease context.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bruinvels, A. T., et al. (2001). "Localization of 5-HT1D, 5-HT1D, 5-HT1F receptors in human brain." Brain Research. Brain Research. 2001. ↩︎ ↩︎
Gabriel, A. (1999). "The 5-HT1D receptor subtype." CNS Drugs. CNS Drugs. 1999. ↩︎
Millan, M. J., et al. (2010). "Serotonin 5-HT1D receptors and antidepressant-like activity." Pharmacology & Therapeutics. Pharmacology & Therapeutics. 2010. ↩︎ ↩︎
Men, Y., et al. (2017). "5-HT1D receptor activation prevents neurodegeneration." Neuropharmacology. Neuropharmacology. 2017. ↩︎
Nepovimova, E., et al. (2019). "Serotonin receptors in Alzheimer's disease." International Journal of Molecular Sciences. International Journal of Molecular Sciences. 2019. ↩︎
Iverson, P. L., et al. (2019). "Serotonin and amyloid-beta interactions." Neurobiology of Disease. Neurobiology of Disease. 2019. ↩︎
Clarke, K. A., et al. (2019). "Serotonergic dysfunction in Parkinson's disease." Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2019. ↩︎
Lanfranco, M. F., et al. (2019). "Serotonergic system in Lewy body dementia." Brain. Brain. 2019. ↩︎
Saft, C., et al. (2019). "Serotonin in Huntington's disease." Journal Huntington's Disease. Journal Huntington's Disease. 2019. ↩︎
Wang, J., et al. (2018). "5-HT1D receptor-mediated neuroprotection in stroke." Stroke. Stroke. 2018. ↩︎
Bartzokis, G., et al. (2007). "Iron and dopamine in aging and Parkinson's disease." Neurobiology of Aging. Neurobiology of Aging. 2007. ↩︎